RESULTS The study cohort included 161 patients with AS who were assigned to TAVR with CV. Of these 11 (7%) patients required a second device implantation at the same procedure due to residual moderate or severe AR. The mean annular diameter in these patients was 26.7 AE 2.6 mm. Valve size of the initial valve was 31mm in 8 patients (73%), 29mm in 2 (18%) and 26mm in 1 patient (9%). Average oversizing was 14 AE 9% and severe valve calcification on CT was present in 6 patients (55%). Procedural characteristics demonstrate a low or high initial implantation in 5 (45%) and 2 (18%) of the patients, respectively. Underexpansion of the initial device was noticed in 6 (54%). The second valve size matched the first valve size in all patients. Immediately post procedure reduction in AR was noted in all but one patient, with 4 (36%) patients reaching grade 2 AR and 6 (54%) patients achieving optimal level of grade 0-1 AR (Figure) . Second valve implantation was safe with no peri-procedural stroke or mortality. However, 6 (55%) patients developed acute kidney injury, 3 (27%) required pacemaker implantation and 4 (36%) developed new left bundle branch block.
CONCLUSIONS Second implantation of CV self-expanding valve for the treatment of significant residual AR is feasible and safe and associated with high immediate success rate, and should be considered as a modality for the treatment of residual moderate or severe AR after CV implantation. METHODS From January to May 2015, an online survey was distributed worldwide in centers performing TAVI regardless the number of procedures and valve type. There was a responsible to distribute the survey in each country or region.
RESULTS A total of 167 centers (with 37843 TAVI procedures performed) responded the questionnaire from 27 different countries in Europe, North-America and South-America. Continuous ECG monitoring following TAVI was maintained during 24, 48 or !72 hours in 23%, 38% and 39% of the centers, respectively. Temporary pacemaker was removed at the end of the procedure in the absence of new conduction disturbances in 27% of patients (45% and 10% following BEV and SEV implantation, respectively). Transient A-V block occurring during valve implantation was usually not an indication for permanent pacemaker implantation for both valve types (>70%). New left bundle branch block was a frequent cause to extend temporary pacemaker indication (SEV 51%; BEV 41%), but not for permanent pacemaker implantation (<2% for both valves). Dual antiplatelet therapy was the most common antithrombotic treatment in patients without atrial fibrillation (89% of centers), with a variable duration (3 months in 44%, 6 months in 31%). In patients with atrial fibrillation, warfarin alone, warfarinþaspirin, warfarinþclopidogrel and triple therapy were given in 35%, 31%, 25% and 3% of the centers, respectively. Patients were followed in a TAVI clinic in only half (46%) of the centers.
CONCLUSIONS This survey highlights important variations in post-TAVI management according to ECG monitoring and temporary pacemaker across centers. Dual antiplatelet therapy is the most common antithrombotic treatment in the absence of other indication for anticoagulation, but antithrombotic treatment in patients with atrial fibrillation is highly variable. Future studies are needed to determine optimal post-TAVI management and follow-up. 
